Challenges posed by COVID‐19 in cancer patients: A narrative review
Authors:
- Zeinab Mohseni AfsharZAZeinab Mohseni Afshar
- Rezvan HosseinzadehRHRezvan Hosseinzadeh
- Mohammad BararyMBMohammad Barary
- Soheil EbrahimpourSoheil Ebrahimpour
- Amirmasoud AlijanpourAAAmirmasoud Alijanpour
- Babak SayadBSBabak Sayad
- Seyed Rouhollah MiriSMSeyed Rouhollah Miri
- Terence T. SioTSTerence T. Sio
- Mark J. M. SullmanMSMark J. M. Sullman
- Kristin Carson‐ChahhoudKCKristin Carson‐Chahhoud
- Arefeh BabazadehABArefeh Babazadeh
Open Access
- 23 December 2021
- journal article
- review article
- Published by Wiley in Cancer Medicine
- Vol. 11 (4) , 1119-1135
Abstract
A novel coronavirus, or severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), was identified as the causative agent of coronavirus disease 2019 (COVID‐19). In early 2020, the World Health Organization declared COVID‐19 the sixth public health emergency of international concern. The COVID‐19 pandemic has substantially affected many groups within the general population, but particularly those with extant clinical conditions, such as having or being treated for cancer. Cancer patients are at a higher risk of developing severe COVID‐19 since the malignancy and chemotherapy may negatively affect the immune system, and their immunocompromised condition also increases the risk of infection. Substantial international efforts are currently underway to develop specific methods for diagnosing and treating COVID‐19. However, cancer patients’ risk profiles, management, and outcomes are not well understood. Thus, the main objective of this review is to discuss the relevant evidence to understand the prognosis of COVID‐19 infections in cancer patients more clearly, as well as helping to improve the clinical management of these patients.Keywords
This publication has 135 references indexed in Scilit:
- Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?Journal for ImmunoTherapy of Cancer, 2019
- Telerehabilitation: Review of the State-of-the-Art and Areas of ApplicationJMIR Rehabilitation and Assistive Technologies, 2017
- Immune Reconstitution after Allogeneic Hematopoietic Stem Cell TransplantationFrontiers in Immunology, 2016
- Toxicities of Immunotherapy for the PractitionerJournal of Clinical Oncology, 2015
- Smoking Cessation Interventions for Lung Cancer PatientsLung Cancer Management, 2013
- Interleukin-6 signaling pathway in targeted therapy for cancerCancer Treatment Reviews, 2012
- Type 1 Interferons and Antiviral CD8 T-Cell ResponsesPLOS Pathogens, 2012
- Obesity and Cancer: The Role of Dysfunctional Adipose TissueCancer Epidemiology, Biomarkers & Prevention, 2009
- Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1991
- [Therapeutic use of alpha interferon in metastasizing malignant melanoma, disseminated Kaposi sarcoma and severe Behçet disease].1987